A recent report on the tremendous predictive value of DPP3 in patients with cardiogenic shock within the ACCOST-HH trial was chosen as one of the 3 best Abstracts out of hundreds submitted for the upcoming 2023 congress of the German Association for Intensive and Emergency Care (DIVI). The scientific congress, one of the largest of its kind in Europe, will take place from November 29th to December 01st in Hamburg / Germany.
Within the study, median circulating DPP3 concentration at baseline was 43.2 ng/mL [21.2-74] and 52% of the patients had elevated DPP3 concentrations over the pre-defined cutoff of 40 ng/mL. The number of days without the need for cardiovascular organ support (pharmacological and/ or mechanical organ support), which had been the primary endpoint of the ACCOST-HH trial, was 7 times longer in the low versus high DPP3 group (21 vs 3 days; p=0.005). Moreover, elevated DPP3 concentrations were associated with the need for mechanical organ support -not just cardiac, but also respiratory (p=0.04; mechanical ventilation) and renal support (p<0.001; renal replacement therapy). The prolonged and increased need for organ support directly translated into a much higher (74% vs 31%) mortality rate in the high DPP3 group.
The PIs commented their findings as follows:
"Our results hold strong promise for the upcoming clinical trials on the evaluation of the specific DPP3-antibody Procizumab as new breakthrough therapy in cardiogenic shock. We are very happy to hear that Procizumab has entered clinical evaluation and might be available to our patients as soon as in 2026/27."
The project is funded by the European Social Fund (ESF) and the Federal State of Brandenburg via the Brandeburg Ministry for Labor, Social Affairs, Health, Women and Family (MASGF).